Committed to a customer service philosophy--to provide service with a passionate focus on results and continuous improvement-- Baxter BioPharma Solutions was a previous recipient of the ViE Award in 2010, 2011, 2012, and 2015. The criteria to be recognized as Best Contract Manufacturing Organization include: the range of services provided in niche and core therapeutic areas; methods of performance improvement or introduction of new services; attention to, and quality of, relationships with clients; milestones reached and final or ongoing outcomes; and building and maintaining existing and long term partnerships.
"Baxter BioPharma Solutions is honored to be recognized by the World Vaccine Congress and the vaccine industry as the best in class," said Marie Keeley, Vice President, BioPharma Solutions. Susan Easton, Plant Manager for Baxter's Bloomington, IN, facility further commented, "Being selected as the Best Contract Manufacturing Organization for the fifth time in eight years demonstrates our commitment to continuous process and customer service improvement to better serve customers and patients worldwide.”
The BioPharma Solutions facility in Bloomington manufactures critical, life-saving products for pharmaceutical and biotechnology companies, and provides a variety of services, including clinical development through commercial launch, formulation, and packaging. The Bloomington facility also has expertise in clinical and commercial vaccines, which includes pandemic, preventative and seasonal vaccines for global markets.
BioPharma Solutions, with its sister contract manufacturing facility in Halle (Westfalen), Germany, works with a majority of the top 20 pharmaceutical companies and currently provides sterile contract manufacturing services to more than 60 clients. The business has been a leader in parenteral contract manufacturing for more than 35 years, offering services for aseptic bags, prefilled syringes, liquid and lyophilized vials and cartridge filling, as well as specialized capabilities for cytotoxics and biologics manufacturing.
The Halle facility completed an approximately 2,000 square meter fill/finish contract manufacturing capacity expansion in 2015. The facility has continued to expand to meet clients’ growing needs for cytotoxic manufacturing, and the most recent expansion further enhanced Halle’s complete range of resources to support early phase drug formulation through commercial scale-up, product launch and lifecycle management.
For additional information on Baxter's BioPharma Solutions business, please visit www.baxterbiopharmasolutions.com.
For additional information on the World Vaccine Congress 2017, please visit http://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm.